Application of RETN and KLK1 serving as tuberculosis detecting markers

A technology of tuberculosis and detection substances, which is applied in the application field of tuberculosis detection markers, can solve the problems of time-consuming, aggravated diagnosis, equipment and diagnosis cost limitations, etc.

Active Publication Date: 2018-02-02
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +1
View PDF6 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Although the sputum smear staining method can produce results on the same day, it cannot distinguish tuberculosis bacilli from non-tuberculous mycobacteria, nor can it distinguish live bacteria from dead bacteria
Although the sensitivity of Mycobacterium tuberculosis culture method is higher, it takes a long time, and it takes 1 month to get the result even for rapid culture.
In addition, for a large number of patients with extrapulmonary tuberculosis and smear-negative or smear-negative tuberculosis, the application of gold standard detection methods is limited, which exacerbates the difficulty of diagnosis and brings resistance to timely treatment.
Although some advanced nucleic acid amplification-based molecular biology detection techniques (such as XpertMTB / RIF assay) have emerged in recent years, they cannot be fully promoted due to the limitations of equipment and diagnostic costs, as well as the high false positive rate.
Therefore, none of the current tuberculosis diagnostic methods or auxiliary diagnostic methods can achieve rapid and effective differential diagnosis of latent infection of Mycobacterium tuberculosis and active tuberculosis, which makes clinical problems such as serious treatment delays and overtreatment

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of RETN and KLK1 serving as tuberculosis detecting markers
  • Application of RETN and KLK1 serving as tuberculosis detecting markers
  • Application of RETN and KLK1 serving as tuberculosis detecting markers

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0046] Embodiment 1, the screening of tuberculosis detection marker

[0047] 1. Screening of differentially expressed genes

[0048] 1. Test subjects

[0049]There were 4 patients with clinically confirmed active tuberculosis (TB), 4 patients with clinically confirmed latent tuberculosis infection (LTBI) and 4 normal subjects (HC). All participants participated voluntarily.

[0050] 2. Microarray screening of differentially expressed genes

[0051] Agilent Whole Human Genome Oligo Microarray (4×44K) (Shanghai Bohao Biochip Co., Ltd.) was used to conduct gene chip analysis on the peripheral blood mononuclear cells of the test subject. The specific steps of the analysis refer to the chip instruction manual. After P2 standard screening to obtain differential gene expression profiles.

[0052] According to the group difference FD>10 and the same trend in TB and LTBI, TB and HC, a total of 13 differentially expressed genes were screened between TB and LTBI groups, and a total of...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of RETN and KLK1 serving as tuberculosis detecting markers. Experiments prove that the RETN gene and the KLK1 gene have evident expression differences in normal tissue, the tissue of a person with latent tuberculosis infection (LTBI) and the tissue of a patient with tuberculosis (TB), the expression level of the RETN gene in the tissue of the patient with tuberculosis (TB) is much higher than that in the normal tissue or in the tissue of the person with latent tuberculosis infection (LTBI), and the expression level of the KLK1 gene in the tissue of the patient with tuberculosis (TB) is much lower than that in the normal tissue or in the tissue of the person with latent tuberculosis infection (LTBI). Therefore, the RETN gene and the KLK1 gene can be usedas the markers for detecting or diagnosing the tuberculosis, and the occurrence and development of the tuberculosis can be monitored.

Description

technical field [0001] The invention belongs to the field of biomedicine, and in particular relates to the application of RETN and KLK1 as tuberculosis detection markers. Background technique [0002] Tuberculosis (TB) is a chronic infectious disease caused by Mycobacterium tuberculosis (M.tb) infection, which seriously threatens human health. The fifth national tuberculosis epidemiological survey shows that there are more than 5 million adults with active pulmonary tuberculosis in China. After adults are infected with Mycobacterium tuberculosis, some of them will live in a carrier state and will not develop tuberculosis, which is called latent tuberculosis infection (LTBI); about 5-10% of latent infections will continue to develop active tuberculosis . The results of epidemiological surveys in various regions in China show that the infection rate of Mycobacterium tuberculosis based on the gamma-interferon release assay (IGRA) is about 20-30%, that is, about 300-400 millio...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C12Q1/6883G01N33/68
CPCG01N33/6893C12Q1/6883G01N2800/50G01N2800/26C12Q2600/158
Inventor 潘丽萍张宗德陈效友高孟秋贾红彦
Owner BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products